Sign in to view content

Updated Safety and Efficacy Results From the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS) for Neovascular AMD

Carl C. Awh, MD, FASRS

Video
Published 2021

Related

Prophylactic Ranibizumab for Exudative AMD in Vulnerable Eyes With Nonexudative AMD Trial (PREVENT) A Prospective Controlled Clinical Trial
Maziar Lalezary, MD, FASRS
Annual Meeting Talks
2018
Outcomes of Patients with DME and Baseline BCVA 20/50 or Worse or 20/40 or Better Treated with Aflibercept 8 mg and 2 mg in the Phase 2/3 PHOTON Trial
Diana V Do, MD, FASRS
Updates from the Field
2024
End-of-Study Retinal Fluid and Vision Outcomes in the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab in Patients With nAMD
Aleksandra V. Rachitskaya, MD, FASRS
Annual Meeting Talks
2022

Category: AMD-Neovascular

See more